Here's a lesson in how the stock market works: positive clinical trial results don't always equal positive stock performance. Zenas BioPharma Inc. (ZBIO) learned this the hard way on Monday, watching its shares crater despite announcing what the company called encouraging Phase 3 data.
The company released results from its INDIGO trial testing obexelimab in patients with Immunoglobulin G4-Related Disease, or IgG4-RD for those of us who don't want to type that out repeatedly. For context, IgG4-RD is a rare immune disorder where your body goes haywire producing too many IgG4 antibodies, causing inflammation and dense tissue growths that can affect multiple organs.
Obexelimab hit its primary endpoint, showing a statistically significant 56% reduction in the risk of disease flares compared to placebo over a 52-week controlled period. The drug also succeeded across all four key secondary endpoints, including reducing investigator-assessed flares, decreasing the need for rescue therapy, helping more patients achieve complete remission, and lowering cumulative rescue therapy use.
On the safety front, infection rates were actually lower in patients taking obexelimab versus placebo, and injection site reactions were similar between groups. Zenas plans to present the full dataset at an upcoming medical conference.
So why did the stock plummet? Competition, pure and simple.
The Amgen Problem
Back in April 2025, the FDA approved Amgen Inc.'s (AMGN) Uplizna as the first and only treatment specifically for adult patients with IgG4-RD. This matters because Amgen already has a massive head start.
Here's where the numbers get uncomfortable for Zenas: Uplizna demonstrated an 87% reduction in flare risk in its MITIGATE trial. Only 10.3% of patients taking Uplizna experienced a flare during the study period, compared to 59.7% of those on placebo. That's objectively better than obexelimab's 56% risk reduction.
Amgen acquired Uplizna through its $27.8 billion purchase of Horizon Therapeutics, so they've got the resources and infrastructure to dominate this space.
Timeline Troubles
Zenas isn't planning to submit its Biologics License Application to the FDA until the second quarter of 2026. That gives Amgen well over a year to establish Uplizna as the standard of care before obexelimab even gets reviewed.
The company also intends to file a Marketing Authorization Application with European regulators in the second half of 2026. Meanwhile, Bristol Myers Squibb Co (BMY) holds exclusive rights to develop and commercialize obexelimab in Japan, South Korea, Taiwan, Hong Kong, Singapore, and Australia under a partnership agreement.
Looking ahead, Zenas expects topline results from a Phase 2 trial testing obexelimab in systemic lupus erythematosus in the fourth quarter of 2026.
The market's message was brutal and clear: being second to market with arguably inferior data isn't a winning formula, even when your trial technically succeeds. Zenas BioPharma shares closed down 53.14% at $16.16 on Monday.
